Low Dose Naltrexone & Pain

The Safety and Efficacy of Low-Dose Naltrexone in the Management of Chronic Pain and Inflammation in Multiple Sclerosis, Fibromyalgia, Crohn's Disease, and Other Chronic Pain Disorders.

 

The Use of Low-Dose Naltrexone for Chronic Pain.

 

Pharmacology Update: Low-Dose Naltrexone as a Possible Nonopioid Modality for Some Chronic, Nonmalignant Pain Syndromes.

 

Low-Dose Naltrexone (LDN)-Review of Therapeutic Utilization.

 

Low-Dose Naltrexone for Chronic Pain: Update and Systemic Review.

 

Low Dose Naltrexone in the Treatment of Fibromyalgia.

 

Use of low-dose naltrexone in the management of chronic pain conditions: A systematic review.

 

Low Dose Naltrexone in Dermatology.

 

The use of low-dose naltrexone (LDN) as a novel anti-inflammatory treatment for chronic pain.

 

Low-dose naltrexone as a treatment for chronic fatigue syndrome.

 

The Use and Utility of Low-dose Naltrexone Capsules for Patients with Fibromyalgia.

 

[Low dose naltrexone for treatment of pain].

 

Low-Dose Naltrexone for the Treatment of Fibromyalgia: Investigation of Dose-Response Relationships.

 

Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.

 

Novel Treatment Using Low-Dose Naltrexone for Lichen Planopilaris.

 

Clinical utility of the cold pressor test: evaluation of pain patients, treatment of opioid-induced hyperalgesia and fibromyalgia with low dose naltrexone.

 

Low-Dose Naltrexone reduces symptoms in Stiff-Person Syndrome.

 

The Use of Naltrexone in Low Doses Beyond the Approved Indication.

 

Variable response to low-dose naltrexone in patients with Darier disease: a case series.

 

Low-dose naltrexone: a novel adjunctive treatment in symptomatic alopecias?

 

LOW-DOSE NALTREXONE REVERSES FACIAL MECHANICAL ALLODYNIA IN A RAT MODEL OF TRIGEMINAL NEURALGIA.

 

Reduced Pro-Inflammatory Cytokines after Eight Weeks of Low-Dose Naltrexone for Fibromyalgia.

 

Treatment of Complex Regional Pain Syndrome (CRPS) using low dose naltrexone (LDN).

 

Intranasal Low-Dose Naltrexone Against Opioid Side Effects: A Preclinical Study.

 

Naltrexone during pain conditioning: A double-blind placebo-controlled experimental trial.

 

Low-Dose Naltrexone Treatment of Familial Benign Pemphigus (Hailey-Hailey Disease).

 

Low-Dose Naltrexone: A New Therapy Option for Complex Regional Pain Syndrome Type I Patients.

 

Oxycodone plus ultra-low-dose naltrexone attenuates neuropathic pain and associated mu-opioid receptor-Gs coupling.

 

Low-dose naltrexone and opioid consumption: a drug utilization cohort study based on data from the Norwegian prescription database.

 

Ultra-Low Doses of Naltrexone Enhance the Antiallodynic Effect of Pregabalin or Gabapentin in Neuropathic Rats.

 

Fibromyalgia symptoms are reduced by low-dose naltrexone: a pilot study.

 

Sjogren's Syndrome and Clinical Benefits of Low-Dose Naltrexone Therapy: Additional Case Reports.

 

Mu-opioid antagonists for opioid-induced bowel dysfunction in people with cancer and people receiving palliative care.

 

Ultra-low dose naltrexone attenuates chronic morphine-induced gliosis in rats.

 

Psychoneuroimmunological approach to gastrointestinal related pain.

 

Sjogren's Syndrome: Clinical Benefits of Low-dose Naltrexone Therapy.

 

Oxytrex: an oxycodone and ultra-low-dose naltrexone formulation.

 

Off-label, low-dose naltrexone for refractory chronic low back pain.

 

Loss of μ opioid receptor signaling in nociceptors, but not microglia, abrogates morphine tolerance without disrupting analgesia.

 

A randomized double-blind, placebo-controlled efficacy and safety study of ALO-02 (extended-release oxycodone surrounding sequestered naltrexone) for moderate-to-severe chronic low back pain treatment.

 

Off-Label, Low-Dose Naltrexone for Refractory Painful Diabetic Neuropathy.

 

Enhancing acupuncture by low dose naltrexone.

 

Low-dose naltrexone for pruritus in systemic sclerosis.

 

Opioid-induced hypogonadism: Pathophysiology, clinical and therapeutics review.

 

Acute thermal hyperalgesia elicited by low-dose morphine in normal mice is blocked by ultra-low-dose naltrexone, unmasking potent opioid analgesia.

 

Long-term benefit from immune modulation and anti-inflammatory treatment in metastatic mesothelioma.

 

Low-dose naltrexone to prevent intolerable morphine adverse events: a forgotten remedy for a neglected, global clinical need.

 

Experimental autoimmune encephalopathy (EAE)-induced hippocampal neuroinflammation and memory deficits are prevented with the non-opioid TLR2/TLR4 antagonist (+)-naltrexone.

 

Potentiation of buprenorphine antinociception with ultra-low dose naltrexone in healthy subjects.

 

Effects of naltrexone exposure observed in two phase three studies with ALO-02, an extended-release oxycodone surrounding sequestered naltrexone.

 

Human abuse liability assessment of oxycodone combined with ultra-low-dose naltrexone.

 

Intermittent blockade of OGFr and treatment of autoimmune disorders.

 

Oxycodone combined with opioid receptor antagonists: efficacy and safety.

 

Biased Opioid Antagonists as Modulators of Opioid Dependence: Opportunities to Improve Pain Therapy and Opioid Use Management.

 

Noradrenaline induces peripheral antinociception by endogenous opioid release.

 

Oral naltrexone to enhance analgesia in patients receiving continuous intrathecal morphine for chronic pain: a randomized, double-blind, prospective pilot study.

 

Naltrexone's Impact on Cancer Progression and Mortality: A Systematic Review of Studies in Humans, Animal Models, and Cell Cultures.

 

A pilot trial of low-dose naltrexone in primary progressive multiple sclerosis.

 

Safety and tolerability of ALO-02 (oxycodone hydrochloride and sequestered naltrexone hydrochloride) extended-release capsules in older patients: a pooled analysis of two clinical trials.

 

Pilot trial of low-dose naltrexone and quality of life in multiple sclerosis.

 

Is there a role for opioids in the treatment of fibromyalgia?

 

Interactions of "ultra-low" doses of naltrexone and morphine in mature and young male and female rats.

 

Low-dose naltreoxone for the treatment of irritable bowel syndrome: a pilot study.

 

Anticonvulsant Effects of Thalidomide on Pentylenetetrazole-Induced Seizure in Mice: A Role for Opioidergic and Nitrergic Transmissions.

 

Paradoxical effects of intracerebroventricular low-dose opioid antagonists in SHR with chronic pain.

 

The effect of low-dose naltrexone on quality of life of patients with multiple sclerosis: a randomized placebo-controlled trial.

 

Morphine sulfate and naltrexone hydrochloride extended-release capsules: naltrexone release, pharmacodynamics, and tolerability.

 

Oxytrex minimizes physical dependence while providing effective analgesia: a randomized controlled trial in low back pain.

 

Evaluation of the Pharmacokinetics of Single- and Multiple-dose Buprenorphine Buccal Film in Healthy Volunteers.

 

Fibromyalgia, autism, and opioid addiction as natural and induced disorders of the endogenous opioid hormonal system.

 

Morphine reduced perceived anger from neutral and implicit emotional expressions.

 

PTI-609: a novel analgesic that binds filamin A to control opioid signaling.

 

Influence of low doses of naltrexone on morphine antinociception and morphine tolerance in male and female rats of four strains.

 

Serotonin induces peripheral antinociception via the opioidergic system.

 

Involvement of μ- and δ-opioid receptor function in the rewarding effect of (±)-pentazocine.

 

Interaction of opioid growth factor (OGF) and opioid antagonist and their significance in cancer therapy.

 

Dipyrone is locally hydrolyzed to 4-methylaminoantipyrine and its antihyperalgesic effect depends on CB2 and kappa-opioid receptors activation.

 

Is fibromyalgia an endocrine/endorphin deficit disorder? Is low dose naltrexone a new treatment option?

 

Involvement of μ-opioid receptors in antinociceptive action of botulinum toxin type A.

 

Paradoxical effects of the opioid antagonist naltrexone on morphine analgesia, tolerance, and reward in rats.

 

Inhibitory effect of low-dose pentazocine on the development of antinociceptive tolerance to morphine.

 

Anxiety and pain: attentional and endorphinergic influences.

 

Ultra-low dose oral naltrexone decreases side effects and potentiates the effect of methadone.

 

Morphine amplifies mechanical allodynia via TLR4 in a rat model of spinal cord injury.

 

Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study.

 

Modulatory effects of Gs-coupled excitatory opioid receptor functions on opioid analgesia, tolerance, and dependence.

 

Nor-Binaltorphimine Blocks the Adverse Effects of Morphine after Spinal Cord Injury.

 

Biochemical and pharmacological characterization of multiple beta-endorphinergic antinociceptive systems in the rat periaqueductal gray.

 

Simultaneous development of opioid tolerance and opioid antagonist-induced receptor upregulation.

 

Endogenous opioids released during non-nociceptive environmental stress induce latent pain sensitization Via a NMDA-dependent process.

 

Nonopioidergic mechanism mediating morphine-induced antianalgesia in the mouse spinal cord.

 

Mechanistic evaluation of tapentadol in reducing the pain perception using in-vivo brain and spinal cord microdialysis in rats.

 

Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice.

 

Epigenetic regulation of spinal cord gene expression controls opioid-induced hyperalgesia.

 

Spinal blockade of opioid receptors prevents the analgesia produced by TENS in arthritic rats.

 

Ultra-low concentrations of naloxone selectively antagonize excitatory effects of morphine on sensory neurons, thereby increasing its antinociceptive potency and attenuating tolerance/dependence during chronic cotreatment.

 

Supraspinal antinociceptive effect of apelin-13 in a mouse visceral pain model.

 

Effects of intravenous methylnaltrexone on opioid-induced gut motility and transit time changes in subjects receiving chronic methadone therapy: a pilot study.

 

Cholera toxin-B subunit blocks excitatory opioid receptor-mediated hyperalgesic effects in mice, thereby unmasking potent opioid analgesia and attenuating opioid tolerance/dependence.

 

Morphine attenuates ultrasonic vocalization during agonistic encounters in adult male rats.

 

Identification and Treatment of New Inflammatory Triggers for Complex Regional Pain Syndrome: Small Intestinal Bacterial Overgrowth and Obstructive Sleep Apnea.

 

Differential effects of specific delta and kappa opioid receptor antagonists on the bidirectional dose-dependent effect of systemic naloxone in arthritic rats, an experimental model of persistent pain.

 

Central antinociception induced by ketamine is mediated by endogenous opioids and μ- and δ-opioid receptors.

 

Naloxone's pentapeptide binding site on filamin A blocks Mu opioid receptor-Gs coupling and CREB activation of acute morphine.

 

The analgesic actions of centrally administered celecoxib are mediated by endogenous opioids.

 

Relative bioavailability of the fentanyl effervescent buccal tablet (FEBT) 1,080 pg versus oral transmucosal fentanyl citrate 1,600 pg and dose proportionality of FEBT 270 to 1,300 microg: a single-dose, randomized, open-label, three-period study in healthy adult volunteers.

 

High-affinity naloxone binding to filamin a prevents mu opioid receptor-Gs coupling underlying opioid tolerance and dependence.

 

Effects of prophylactic nalmefene on the incidence of morphine-related side effects in patients receiving intravenous patient-controlled analgesia.

 

Shock controllability and opioid substrates of escape performance and nociception: differential effects of peripherally and centrally acting naltrexone.

 

Supraspinal anti-allodynic and rewarding effects of endomorphins in rats.

 

Involvement of peripheral cannabinoid and opioid receptors in β-caryophyllene-induced antinociception.

 

A control systems engineering approach for adaptive behavioral interventions: illustration with a fibromyalgia intervention.

 

Safety and efficacy of an oxycodone vaccine: Addressing some of the unique considerations posed by opioid abuse.

 

The highly selective delta agonist BUBU induces an analgesic effect in normal and arthritic rat and this action is not affected by repeated administration of low doses of morphine.

 

High dose of spinal morphine produce a nonopiate receptor-mediated hyperesthesia: clinical and theoretic implications.

 

Pharmacological, pharmacokinetic, and primate analgesic efficacy profile of the novel bradykinin B1 Receptor antagonist ELN441958.

 

THC-methadone and THC-naltrexone interactions on discrimination, antinociception, and locomotion in rats.

 

Beta-endorphin differentially affects inflammation in two inbred rat strains.

 

Hyperalgesic and analgesic actions of morphine, U50-488, naltrexone, and (-)-lobeline in the rat brainstem.

 

An efficient intrathecal delivery of small interfering RNA to the spinal cord and peripheral neurons.

 

Rapid opioid detoxification during general anesthesia: a review of 20 patients.

 

alpha-Adrenoceptor and opioid receptor modulation of clonidine-induced antinociception.

 

Kappa opioid receptors participate in nerve growth factor-induced hyperalgesia.

 

Further evidence for a peripheral component in the enhanced antinociceptive effect of systemic morphine in mononeuropathic rats: involvement of kappa-, but not delta-opioid receptors.

 

Antinociceptive profiles of platycodin D in the mouse.

 

Peripheral component in the enhanced antinociceptive effect of systemic U-69,593, a kappa-opioid receptor agonist in mononeuropathic rats.

 

Opioid receptor internalization contributes to dermorphin-mediated antinociception.

 

Sexual dimorphism in the antinociception mediated by kappa opioid receptors in the rat temporomandibular joint.

 

Pharmacological profile of a deuterium-substituted mirfentanil derivative, OHM10579, in rhesus monkeys.

 

Inescapable shock-induced potentiation of morphine analgesia in rats: involvement of opioid, GABAergic, and serotonergic mechanisms in the dorsal raphe nucleus.

 

Antinociceptive and antitussive effects of morphine in the DA-bg/bg (beige) rat.

 

Methocinnamox is a potent, long-lasting, and selective antagonist of morphine-mediated antinociception in the mouse: comparison with clocinnamox, beta-funaltrexamine, and beta-chlornaltrexamine.

 

The cold plate as a test of nociceptive behaviors: description and application to the study of chronic neuropathic and inflammatory pain models.

 

Blockade of opioid receptors in rostral ventral medulla prevents antihyperalgesia produced by transcutaneous electrical nerve stimulation (TENS).

 

Augmentation of spinal morphine analgesia and inhibition of tolerance by low doses of mu- and delta-opioid receptor antagonists.

 

The use of specific opioid agonists and antagonists to delineate the vagally mediated antinociceptive and cardiovascular effects of intravenous morphine.

 

Inhibition of morphine-induced analgesia and locomotor activity in strains of mice: a comparison of long-acting opiate antagonists.

 

Severe pruritus of cholestasis in disseminated cancer: developing a rational treatment strategy. A case report.

 

Effects of N-methylnaloxone and N-methylnaltrexone on nociception and precipitated abstinence in mice.

 

Behavioral evidence for cholecystokinin-opiate interactions in neonatal rats.

 

The development of morphine-induced antinociception in neonatal rats: a comparison of forepaw, hindpaw, and tail retraction from a thermal stimulus.

 

Antinociceptive and behavioral effects of synthetic deltorphin analogs.

 

Modulation of cocaine-induced antinociception by opioid-receptor agonists.